HIVE vs HUT

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 11, 2026

HIVE

57.4
AI Score
VS
HIVE Wins

HUT

44.4
AI Score

Investment Advisor Scores

HIVE

57score
Recommendation
BUY

HUT

44score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric HIVE HUT Winner
Forward P/E 62.8931 138.8889 HIVE
PEG Ratio 0 0 Tie
Revenue Growth 73.5% 81.4% HUT
Earnings Growth -99.9% 6006.8% HUT
Tradestie Score 57.4/100 44.4/100 HIVE
Profit Margin -98.5% -188.6% HIVE
Beta 1.00 1.00 Tie
AI Recommendation BUY HOLD HIVE

Relative Price Performance (Last 90 Days)

HIVE 1M: +10.6% · 3M: -20.1% HUT 1M: +8.6% · 3M: -15.2%

Current Technical Phase

HIVE

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 52

RSI (14): 51.8 · Price: $3.03

HUT

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 56

RSI (14): 56.3 · Price: $98.60

Fundamentals Snapshot

Metric HIVE HUT
Market Cap
Forward P/E -5.9 -19.0
Trailing P/E
Revenue (TTM)
Revenue Growth 0.7% 0.8%
Gross Margin 0.4% 0.6%
Operating Margin -0.6% -2.8%
EPS -1.33 -5.10
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.